Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Oct;39(10):2289–2294. doi: 10.1128/aac.39.10.2289

Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis.

G Perdikaris 1, H Giamarellou 1, A Pefanis 1, I Donta 1, P Karayiannakos 1
PMCID: PMC162931  PMID: 8619584

Abstract

Using a rabbit model of aortic valve endocarditis, we studied the efficacy of vancomycin alone or in combination with netilmicin and/or rifampin against a methicillin- and gentamicin-resistant strain of Staphylococcus aureus (MGRSA). Antibiotics were given for 6 to 12 days, as follows: vancomycin (15 mg/kg of body weight every 12 h [BID] intravenously), vancomycin plus netilmicin (2.5 mg/kg BID intramuscularly), vancomycin plus rifampin (10 mg/kg BID intramuscularly), and vancomycin plus netilmicin plus rifampin at the same routes, dosages, and schedules mentioned above. Netilmicin was given to two additional groups at a higher dosage (6 mg/kg every 24 h intramuscularly) alone or in combination with vancomycin (15 mg/kg BID intravenously) for 12 days. All regimens resulted in undetectable bacterial counts in a significant proportion of vegetations (except netilmicin alone) or reduced the bacterial counts in the vegetations compared with the counts in the untreated controls (P<0.01 to P<0.001). No resistance to rifampin or netilmicin developed during therapy. It is concluded that in the treatment of experimental aortic valve endocarditis caused by MGRSA (i) vancomycin as monotherapy is as efficacious as the triple combination, (ii) the addition of netilmicin (once daily or BID) to vancomycin does not improve the efficacy of the latter antibiotic, even in the presence of rifampin, and (iii) a 12-day course in more effective than a 6-day one, but not at a statistically significant level.

Full Text

The Full Text of this article is available as a PDF (214.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bayer A. S., Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985 Jan;151(1):157–165. doi: 10.1093/infdis/151.1.157. [DOI] [PubMed] [Google Scholar]
  2. Bayer A. S., Morrison J. O. Disparity between timed-kill and checkerboard methods for determination of in vitro bactericidal interactions of vancomycin plus rifampin versus methicillin-susceptible and -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Aug;26(2):220–223. doi: 10.1128/aac.26.2.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boyce J. M. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am. 1989 Dec;3(4):901–913. [PubMed] [Google Scholar]
  4. Carrizosa J., Kaye D. Antibiotic concentrations in serum, serum bactericidal activity, and results of therapy of streptococcal endocarditis in rabbits. Antimicrob Agents Chemother. 1977 Oct;12(4):479–483. doi: 10.1128/aac.12.4.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carrizosa J., Kaye D. Penicillin and netilmicin in treatment of experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1978 Mar;13(3):505–508. doi: 10.1128/aac.13.3.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chambers H. F. Methicillin-resistant staphylococci. Clin Microbiol Rev. 1988 Apr;1(2):173–186. doi: 10.1128/cmr.1.2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chambers H. F., Sande M. A. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1984 Jul;26(1):61–64. doi: 10.1128/aac.26.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Coleman D. L., Horwitz R. I., Andriole V. T. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis. Am J Med. 1982 Aug;73(2):260–267. doi: 10.1016/0002-9343(82)90188-7. [DOI] [PubMed] [Google Scholar]
  9. Contrepois A., Brion N., Garaud J. J., Faurisson F., Delatour F., Levy J. C., Deybach J. C., Carbon C. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother. 1985 Apr;27(4):520–524. doi: 10.1128/aac.27.4.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Crossley K., Loesch D., Landesman B., Mead K., Chern M., Strate R. An outbreak of infections caused by strains of Staphylococcus aureus resistant to methicillin and aminoglycosides. I. Clinical studies. J Infect Dis. 1979 Mar;139(3):273–279. doi: 10.1093/infdis/139.3.273. [DOI] [PubMed] [Google Scholar]
  11. Daschner F. D., Frank U. Antimicrobial drugs in human cardiac valves and endocarditic lesions. J Antimicrob Chemother. 1987 Dec;20(6):776–782. doi: 10.1093/jac/20.6.776. [DOI] [PubMed] [Google Scholar]
  12. French G. L., Ling J. L., Hui Y. W., Oo H. K. Determination of methicillin-resistance in Staphylococcus aureus by agar dilution and disc diffusion methods. J Antimicrob Chemother. 1987 Oct;20(4):599–608. doi: 10.1093/jac/20.4.599. [DOI] [PubMed] [Google Scholar]
  13. Geraci J. E., Wilson W. R. Vancomycin therapy for infective endocarditis. Rev Infect Dis. 1981 Nov-Dec;3 Suppl:S250–S258. [PubMed] [Google Scholar]
  14. Godfrey K. Statistics in practice. Comparing the means of several groups. N Engl J Med. 1985 Dec 5;313(23):1450–1456. doi: 10.1056/NEJM198512053132305. [DOI] [PubMed] [Google Scholar]
  15. Gopal V., Bisno A. L., Silverblatt F. J. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA. 1976 Oct 4;236(14):1604–1606. [PubMed] [Google Scholar]
  16. Hackbarth C. J., Chambers H. F., Sande M. A. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 1986 Apr;29(4):611–613. doi: 10.1128/aac.29.4.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jolley M. E. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol. 1981 Sep-Oct;5(5):236–240. doi: 10.1093/jat/5.5.236. [DOI] [PubMed] [Google Scholar]
  18. Kaatz G. W., Barriere S. L., Schaberg D. R., Fekety R. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1987 Apr;31(4):527–530. doi: 10.1128/aac.31.4.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  20. Karchmer A. W. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med. 1985 Jun 28;78(6B):116–127. doi: 10.1016/0002-9343(85)90374-2. [DOI] [PubMed] [Google Scholar]
  21. Levine D. P., Fromm B. S., Reddy B. R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991 Nov 1;115(9):674–680. doi: 10.7326/0003-4819-115-9-674. [DOI] [PubMed] [Google Scholar]
  22. Luft F. C., Yum M. N., Kleit S. A. Comparative nephrotoxicities of netilmicin and gentamicin in rats. Antimicrob Agents Chemother. 1976 Nov;10(5):845–849. doi: 10.1128/aac.10.5.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mandell G. L., Vest T. K. Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. J Infect Dis. 1972 May;125(5):486–490. doi: 10.1093/infdis/125.5.486. [DOI] [PubMed] [Google Scholar]
  24. Mulligan M. E., Murray-Leisure K. A., Ribner B. S., Standiford H. C., John J. F., Korvick J. A., Kauffman C. A., Yu V. L. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med. 1993 Mar;94(3):313–328. doi: 10.1016/0002-9343(93)90063-u. [DOI] [PubMed] [Google Scholar]
  25. Perlman B. B., Freedman L. R. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med. 1971 Oct;44(2):206–213. [PMC free article] [PubMed] [Google Scholar]
  26. Reymann M. T., Holley H. P., Jr, Cobbs C. G. Persistent bacteremia in staphylococcal endocarditis. Am J Med. 1978 Nov;65(5):729–737. doi: 10.1016/0002-9343(78)90790-8. [DOI] [PubMed] [Google Scholar]
  27. Small P. M., Chambers H. F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227–1231. doi: 10.1128/aac.34.6.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Watanakunakorn C., Guerriero J. C. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Jun;19(6):1089–1091. doi: 10.1128/aac.19.6.1089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  30. Zak O., Scheld W. M., Sande M. A. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev Infect Dis. 1983 Jul-Aug;5 (Suppl 3):S481–S490. doi: 10.1093/clinids/5.supplement_3.s481. [DOI] [PubMed] [Google Scholar]
  31. Zinner S. H., Lagast H., Klastersky J. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis. 1981 Oct;144(4):365–371. doi: 10.1093/infdis/144.4.365. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES